Guidelines for myelofibrosis were produced in 2012 (Reilly et al, 2012), but since then Ruxolitinib, a JAK1/JAK2 inhibitor, has been approved for use in the European Union and highly prevalent mutations in the Calreticulin gene (CALR) have been described.
Incyte announced that it will discontinue the Phase III LIMBER-304 trial following results of a pre-planned interim analysis conducted by an independent data monitoring committee (IDMC) indicating that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population. The recommendation to stop the study was not due to safety.
MorphoSys AG announced strong topline results from the Phase III MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib compared with placebo plus ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis
Novartis has announced that five-year treatment with Jakafi (ruxolitinib) suggested an overall survival advantage for patients with myelofibrosis (MF), despite...
Sierra Oncology, Inc. announced it has acquired the drug candidate momelotinib from Gilead Sciences. Momelotinib has been investigated in two...